Saturday 17 October 2026
Export DCOY’s income statement to Excel — free account
Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow DCOY
Decoy Therapeutics Inc (DCOY) P/E ratio
As of 16 October 2026, Decoy Therapeutics Inc (DCOY) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (March 2026) to 0.1× (June 2026); the current reading is higher than 95% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.1×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VIVS VivoSim Labs, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| ARAV ARAVIVE, INC compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| ONCO Onconetix, Inc. compare | 0.0× |
| DCOY Decoy Therapeutics Inc | 0.0× |
| GRI GRI Bio, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)